(Q33382497)

26 July 2017

title

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients (English)

1 reference

26 July 2017

main subject

phase I clinical trial

0 references

1 reference

1 reference

1 reference

J-L Li

1

1 reference

26 July 2017

H-L Liu

2

1 reference

26 July 2017

X-R Zhang

3

1 reference

26 July 2017

J-P Xu

4

1 reference

26 July 2017

W-K Hu

5

1 reference

26 July 2017

M Liang

6

1 reference

26 July 2017

S-Y Chen

7

1 reference

26 July 2017

F Hu

8

1 reference

26 July 2017

D-T Chu

9

1 reference

26 July 2017

publication date

25 December 2008

1 reference

26 July 2017

1 reference

26 July 2017

volume

16

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

376-382

1 reference

https://scigraph.springernature.com/pub.10.1038/gt.2008.179

26 July 2017

exact match

0 references

cites work

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

China approves world's first oncolytic virus therapy for cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

The end of the beginning: oncolytic virotherapy achieves clinical proof-of-concept

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Clinical trials with oncolytic adenovirus in China

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Role of the major heat shock proteins as molecular chaperones

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

CD91: a receptor for heat shock protein gp96

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Heat shock protein 90: the cancer chaperone

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Hsp90 as a capacitor of phenotypic variation

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

The Hsp90 chaperone complex as a novel target for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Biosafety of adenoviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Effects of febrile temperature on adenoviral infection and replication: implications for viral therapy of cancer.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Differences between the effects of EDTA and citrate anticoagulants on platelet count and mean platelet volume

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Improving T cell therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

A listing of human tumor antigens recognized by T cells: March 2004 update

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Reverse ELISPOT assay for clonal analysis of cytokine production I. Enumeration of gamma-interferon-secreting cells

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Phenotypic analysis of antigen-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Some practical improvements in the continual reassessment method for phase I studies.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.179

7 January 2021

Identifiers

DOI

10.1038/GT.2008.179

1 reference

26 July 2017

1 reference